A Phase 3 interventional study of Oleogel-S10 and Control gel in Epidermolysis Bullosa, sponsored by Amryt Research Limited. Completed at 51 sites in 26 countries. Open to participants aged 21 Days and older. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Amryt Research Limited (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one has the largest enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 8 in phase 3, and was the 16th registered.
86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.
Browse Epidermolysis Bullosa studies →10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 5–21
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
BioMendics, LLC · Sites in United States
Ages 2+
M. Peter Marinkovich · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 21 Days and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 8
First in 2007; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 15 across 68 interventional studies indexed under Epidermolysis Bullosa.
Median enrollment 16 across the 37 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amryt Research Limited, one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
This is the only study on the registry with Amryt Research Limited as lead sponsor.
Chiesi Farmaceutici S.p.A. has 3 studies filed under Epidermolysis Bullosa — fewer than ten, so there is no comparison to draw.
6 of the studies in Epidermolysis Bullosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT07050810Northwestern UniversityThera-Clean® Microbubbles System in Patients With Skin Diseases | 2027-06 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB).
EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response to minor injury. In most cases, onset of EB is at birth or shortly after. All participants affected by any type of EB share the main characteristic of repeatedly developing painful wounds that take days to months to heal. Current treatment of EB is primarily preventative and supportive including protection from mechanical forces by avoiding rubbing, early treatment of wounds to prevent infections, and protection of the wound with adequate non-adhesive dressings to enable healing.
The active pharmaceutical ingredient in Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin.
This clinical study of Oleogel-S10 in patients with inherited EB has been carried out to investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe for long-term use.
Oleogel-S10 was compared to a control gel. The control gel matched Oleogel-S10 in terms of texture and visual appearance to allow for double-blinding. The packaging for Oleogel-S10 gel and the control gel were identical. The participant received either Oleogel-S10 or control gel for a double-blind study phase of 90 days. The probability that the participant received Oleogel-S10 was 50%, which means that they had a 1 in 2 chance of receiving Oleogel-S10. However, in the follow-up phase of the study all participants were treated with Oleogel-S10 for a period of 24 months.
This clinical study was performed at 49 study sites in 26 countries (Argentina, Australia, Austria, Brazil, Chile, Colombia, Czech Republic, Denmark, France, Georgia, Germany, Greece, Hong Kong [China], Hungary, Ireland, Israel, Italy, Romania, Russia, Serbia, Singapore, Spain, Switzerland, Ukraine, United Kingdom, and the United States); 223 participants participated in total.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Oleogel-S10
Drug: Control gel
Drug pages: Episalvan · Birch triterpenes
10% birch bark extract in 90% sunflower oil
Also known as: Episalvan, Filsuvez
Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
Also known as: Vehicle gel
Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment
Proportion of subjects with first complete closure of the EB target wound (defined as EB partial-thickness wound of 10 cm2 to 50 cm2 in size and ≥21 days to \<9 months in age) in subjects with inherited EB (subtypes DEB, JEB, or Kindler EB) within 45 days of treatment with Oleogel-S10 compared to control gel based on clinical assessment by the investigator (the wound was rated as "closed" at first appearance of complete re-epithelialization without drainage).
Time frame: 45±7 days
Time to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP)
The first key secondary endpoint was time to first complete closure of the EB target wound as evidenced by clinical assessment within 90 days or by EDBP, using a nonstratified log-rank test. If the primary analysis of the primary efficacy endpoint showed superiority at the 5% significance level, hierarchical confirmatory testing of the 6 key secondary endpoints was to be performed.
Time frame: 90±7 days
Proportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP
The second key secondary endpoint was the proportion of subjects with first complete closure of the EB target wound within 90 days of treatment or by EDBP based on clinical assessment by the investigator.
Time frame: 90±7 days
The Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection)
The incidence of EB target wound infections between Baseline (DBP D0) and D90 or EDBP was assessed based on the total number of patients with an EB target wound infection, as evidenced by AEs and/or the use of topical and/or systemic antibiotics, and the total number of patients
Time frame: 90±7 days
The Maximum Severity of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by AEs
Target wound infections between baseline (DBP D0) and D90 or EDBP were assessed for maximum severity (maximum severity was evaluated if a subject had a wound infection event evidenced by AEs). \[Note: Here, 1 event less is recorded in the control gel group as for the previous secondary outcome measure, because only wound infections that were reported as AEs could be assessed for severity and were included in this analysis.\]
Time frame: 90±7 days
Change From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP
The evaluation of total body wound burden (TBWB) was based on clinical assessment using Section I (Skin) of the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). The EBDASI skin activity (blistering/erosions/crusting) was scored from 0 to 10 for each of 10 anatomical locations (excluding the anogenital and buttocks regions). Therefore, the total skin activity score (i.e., TBWB) could range from 0 to 100, with lower scores indicative of less wound burden. The change in TBWB was assessed from baseline (DBP D0) to D90 or EDBP.
Time frame: 90±7 days
Change From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients ≥ 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP
Change from Baseline at D90 or EDBP on the Itch Man Scale in patients 4-13 years of age. The scale runs from 0 (comfortable, no itch) to 4 (itches most terribly, impossible to sit still, concentrate).
Time frame: 90±7 days
Change From Baseline (DBP D0) in Itching Using the 'Leuven Itch Scale' in Patients ≥ 14 Years of Age Before Wound Dressing Changes at D90 or End of Double Blind Phase (EDBP)
Change in Leuven Itch Scale (patients ≥ 14 years of age) scores taken from two time points, Baseline and Day 90±7 \[End of Double Blind Phase (EDBP)\]. The Leuven Itch Scale measures six dimensions of the itch experience: Frequency Subscore (0 = Never to 100 = Always); Duration Subscore (0 = Between 0 and 30 minutes to 100 = More than 2 hours); Severity Subscore (0 = No itch to 100 = Worst possible itch); Consequences Subscore \[0 = Never to 100 = Always (lower score indicates less negative consequences from the itch)\]; Distress Subscore (0 = Not distressing at all to 100 = Very distressing); Surface Area Subscore (0-100, high values indicate more parts of the body are itching)
Time frame: 90±7 days
| Milestone | Oleogel-S10 | Control Gel |
|---|---|---|
| Started | 109 | 114 |
| Completed | 100 | 99 |
| Not completed | 9 | 15 |
| Milestone | Oleogel-S10 | Control Gel |
|---|---|---|
| Started | 100 | 105 |
| Completed | 66 | 75 |
| Not completed | 34 | 30 |
Proportion of subjects with first complete closure of the EB target wound (defined as EB partial-thickness wound of 10 cm2 to 50 cm2 in size and ≥21 days to \<9 months in age) in subjects with inherited EB (subtypes DEB, JEB, or Kindler EB) within 45 days of treatment with Oleogel-S10 compared to control gel based on clinical assessment by the investigator (the wound was rated as "closed" at first appearance of complete re-epithelialization without drainage).
| Participants | Oleogel-S10 | Control Gel |
|---|---|---|
| Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment | 45 | 33 |
The first key secondary endpoint was time to first complete closure of the EB target wound as evidenced by clinical assessment within 90 days or by EDBP, using a nonstratified log-rank test. If the primary analysis of the primary efficacy endpoint showed superiority at the 5% significance level, hierarchical confirmatory testing of the 6 key secondary endpoints was to be performed.
| days | Oleogel-S10 | Control Gel |
|---|---|---|
| Time to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP) | 92.0 (50 to NA) | 94.0 (89 to NA) |
The second key secondary endpoint was the proportion of subjects with first complete closure of the EB target wound within 90 days of treatment or by EDBP based on clinical assessment by the investigator.
| Participants | Oleogel-S10 | Control Gel |
|---|---|---|
| Proportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP | 55 | 50 |
The incidence of EB target wound infections between Baseline (DBP D0) and D90 or EDBP was assessed based on the total number of patients with an EB target wound infection, as evidenced by AEs and/or the use of topical and/or systemic antibiotics, and the total number of patients
| Participants | Oleogel-S10 | Control Gel |
|---|---|---|
| The Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection) | 1 | 5 |
Target wound infections between baseline (DBP D0) and D90 or EDBP were assessed for maximum severity (maximum severity was evaluated if a subject had a wound infection event evidenced by AEs). \[Note: Here, 1 event less is recorded in the control gel group as for the previous secondary outcome measure, because only wound infections that were reported as AEs could be assessed for severity and were included in this analysis.\]
| Participants | Oleogel-S10 | Control Gel |
|---|---|---|
| Maximum severity of wound infection: Mild | 1 | 0 |
| Maximum severity of wound infection: Moderate | 0 | 3 |
| Maximum severity of wound infection: Severe | 0 | 1 |
| No wound infection | 108 | 110 |
The evaluation of total body wound burden (TBWB) was based on clinical assessment using Section I (Skin) of the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). The EBDASI skin activity (blistering/erosions/crusting) was scored from 0 to 10 for each of 10 anatomical locations (excluding the anogenital and buttocks regions). Therefore, the total skin activity score (i.e., TBWB) could range from 0 to 100, with lower scores indicative of less wound burden. The change in TBWB was assessed from baseline (DBP D0) to D90 or EDBP.
| score on a scale | Oleogel-S10 | Control Gel |
|---|---|---|
| Change From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP | -0.44 ± 0.90 | -0.56 ± 0.85 |
Change from Baseline at D90 or EDBP on the Itch Man Scale in patients 4-13 years of age. The scale runs from 0 (comfortable, no itch) to 4 (itches most terribly, impossible to sit still, concentrate).
| score on a scale | Oleogel-S10 | Control Gel |
|---|---|---|
| Change From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients ≥ 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP | -0.44 ± 1.31 | -1.00 ± 1.31 |
Change in Leuven Itch Scale (patients ≥ 14 years of age) scores taken from two time points, Baseline and Day 90±7 \[End of Double Blind Phase (EDBP)\]. The Leuven Itch Scale measures six dimensions of the itch experience: Frequency Subscore (0 = Never to 100 = Always); Duration Subscore (0 = Between 0 and 30 minutes to 100 = More than 2 hours); Severity Subscore (0 = No itch to 100 = Worst possible itch); Consequences Subscore \[0 = Never to 100 = Always (lower score indicates less negative consequences from the itch)\]; Distress Subscore (0 = Not distressing at all to 100 = Very distressing); Surface Area Subscore (0-100, high values indicate more parts of the body are itching)
| score on a scale | Oleogel-S10 | Control Gel |
|---|---|---|
| Frequency subscore (change from baseline) | -8.13 ± 26.18 | -10.14 ± 27.3 |
| Duration subscore (change from baseline) | -0.93 ± 35.174 | 0.98 ± 39.768 |
| Severity subscore (change from baseline) | -4.95 ± 19.33 | -10.76 ± 32.68 |
| Consequences subscore (change from baseline) | -4.39 ± 14.073 | -3.54 ± 19.402 |
| Distress subscore (change from baseline) | -0.44 ± 22.87 | -0.26 ± 34.87 |
| Surface area subscore (change from baseline) | -1.54 ± 12.347 | 0.68 ± 17.082 |
Collected over DBP D0 to the last dose of study medication at Month 24 (OLP) ±14 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oleogel-S10 (DBP) | 0/109 (0%) | 7/109 (6.4%) | 89/109 (81.7%) |
| Control Gel (DBP) | 0/114 (0%) | 6/114 (5.3%) | 92/114 (80.7%) |
| Former Oleogel-S10 (OLP) | 7/100 (7%) | 26/100 (26%) | 77/100 (77%) |
| Former Control Gel (OLP) | 2/105 (1.9%) | 24/105 (22.9%) | 81/105 (77.1%) |
| Event | Oleogel-S10 (DBP) | Control Gel (DBP) | Former Oleogel-S10 (OLP) | Former Control Gel (OLP) |
|---|---|---|---|---|
| Oesophageal stenosisGastrointestinal disorders | 0/109 | 0/114 | 4/100 | 6/105 |
| AnaemiaBlood and lymphatic system disorders | 3/109 | 0/114 | 4/100 | 6/105 |
| Squamous cell carcinoma skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/109 | 0/114 | 3/100 | 0/105 |
| septic shockInfections and infestations | 0/109 | 0/114 | 2/100 | 1/105 |
| BacteraemiaInfections and infestations | 0/109 | 0/114 | 2/100 | 0/105 |
| COVID-19Infections and infestations | 0/109 | 0/114 | 2/100 | 0/105 |
| PseudosyndactylyMusculoskeletal and connective tissue disorders | 0/109 | 0/114 | 2/100 | 0/105 |
| Wound infectionInfections and infestations | 0/109 | 1/114 | 1/100 | 2/105 |
| Rectal haemorrhageGastrointestinal disorders | 0/109 | 0/114 | 0/100 | 2/105 |
| MalnutritionMetabolism and nutrition disorders | 0/109 | 0/114 | 1/100 | 2/105 |
| Event | Oleogel-S10 (DBP) | Control Gel (DBP) | Former Oleogel-S10 (OLP) | Former Control Gel (OLP) |
|---|---|---|---|---|
| Wound complicationInjury, poisoning and procedural complications | 67/109 | 61/114 | 38/100 | 46/105 |
| AnaemiaBlood and lymphatic system disorders | 8/109 | 4/114 | 16/100 | 21/105 |
| Wound infectionInfections and infestations | 8/109 | 10/114 | 6/100 | 15/105 |
| PyrexiaGeneral disorders | 9/109 | 15/114 | 10/100 | 10/105 |
| Wound infection staphylococcalInfections and infestations | 4/109 | 3/114 | 9/100 | 12/105 |
| Oesophageal stenosisGastrointestinal disorders | 0/109 | 1/114 | 8/100 | 11/105 |
| Wound infection bacterialInfections and infestations | 3/109 | 5/114 | 7/100 | 9/105 |
| PruritusSkin and subcutaneous tissue disorders | 8/109 | 6/114 | 5/100 | 9/105 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/109 | 8/114 | 2/100 | 1/105 |
| DysphagiaGastrointestinal disorders | 2/109 | 1/114 | 6/100 | 7/105 |
| Age, Customized(Participants) | Oleogel-S10 | Control Gel | Total |
|---|---|---|---|
| < 4 years | 7 | 10 | 17 |
| 4 to <12 years | 42 | 43 | 85 |
| 12 to <18 years | 25 | 29 | 54 |
| 18 years and older | 35 | 32 | 67 |
| Sex: Female, Male(Participants) | Oleogel-S10 | Control Gel | Total |
|---|---|---|---|
| Female | 41 | 48 | 89 |
| Male | 68 | 66 | 134 |
| Race/Ethnicity, Customized(Participants) | Oleogel-S10 | Control Gel | Total |
|---|---|---|---|
| White | 95 | 91 | 186 |
| Black or African American | 1 | 2 | 3 |
| Asian | 4 | 7 | 11 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Unknown | 1 | 1 | 2 |
| Not applicable (applies in countries where the collection of race was prohibited) | 4 | 8 | 12 |
| Other (applies if none of the races listed were appropriate or if the subject was of mixed race) | 4 | 4 | 8 |
| Region of Enrollment(participants) | Oleogel-S10 | Control Gel | Total |
|---|---|---|---|
| Europe | 48 | 55 | 103 |
| South America | 33 | 35 | 68 |
| United States | 7 | 7 | 14 |
| Australia | 6 | 2 | 8 |
| Georgia | 1 | 3 | 4 |
| Hong Kong | 0 | 2 | 2 |
| Israel | 9 | 4 | 13 |
| Russia | 4 | 4 | 8 |
| Singapore | 1 | 1 | 2 |
| Ukraine | 0 | 1 | 1 |
| Epidermolysis Bullosa Subtype(Participants) | Oleogel-S10 | Control Gel | Total |
|---|---|---|---|
| RDEB (recessive dystrophic epidermolysis bullosa) | 91 | 84 | 175 |
| DDEB (dominant dystrophic epidermolysis bullosa) | 6 | 14 | 20 |
| JEB (junctional epidermolysis bullosa) | 11 | 15 | 26 |
| EBS (epidermolysis bullosa simplex) | 1 | 1 | 2 |
| Kindler EB | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m²) | Oleogel-S10 | Control Gel | Total |
|---|---|---|---|
| Mean | 16.05 ± 4.979 | 16.31 ± 5.037 | 16.18 ± 4.999 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Jun 2020, 38 months.
Results were first posted in Jul 2023, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Episalvan · Birch triterpenes